- Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”
-
Yim SY, Lee SH, Kim JH, Lee SS, Kaseb AO, Lee JS
- KMID: 2563467
- Clin Mol Hepatol.
- 2025 Jan;31(1):e84-e86.
- doi: 10.3350/cmh.2024.0830
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
-
Lee SH, Yim SY, Kim JH, Lee SS, Kaseb AO, Lee JS
- KMID: 2563466
- Clin Mol Hepatol.
- 2025 Jan;31(1):e81-e83.
- doi: 10.3350/cmh.2024.0829
-
- CITED
-
- Close
- SHARE
-
- Close
- Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Lee SH, Yim SY, Kim JH, Lee SS, Kaseb AO, Wei P, Lee JS
- KMID: 2563477
- Clin Mol Hepatol.
- 2025 Jan;31(1):e110-e112.
- doi: 10.3350/cmh.2024.0828
-
- CITED
-
- Close
- SHARE
-
- Close
- Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
-
Yim SY, Lee SH, Baek SW, Sohn B, Jeong YS, Kang SH, Park K, Park H, Lee SS, Kaseb AO, Park YN, Leem SH, Curran MA, Kim JH, Lee JS
- KMID: 2560087
- Clin Mol Hepatol.
- 2024 Oct;30(4):807-823.
- doi: 10.3350/cmh.2024.0333
Background/Aims: Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response... -
- CITED
-
- Close
- SHARE
-
- Close
